At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,020 enrolled
Drug / intervention
BMS-986165 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study With Randomized Withdrawal and Retreatment to Evaluate the Efficacy and Safety of BMS-986165 in Subjects With Moderate-to-Severe Plaque Psoriasis
In Brief
A Phase 3 clinical trial evaluating BMS-986165, Placebo, and 1 other intervention for Psoriasis. Completed, enrolled 1,020 participants across 205 sites in 16 countries.
Detailed Summary
The purpose of this study is to investigate the experimental medication BMS-986165 compared to placebo and a currently available treatment in participants with moderate to severe plaque psoriasis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis
CountriesAustralia, Canada, Czechia, Finland, France, Germany, Hungary, Israel, Italy, New Zealand, Poland, Puerto Rico, Spain, Sweden, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20192020202120222023202420252026
Enrollment StartJul 2018
First PostedAug 2018
Primary CompletionNov 2020
Study CompletionNov 2020
TodayJul 2026
First PostedAug 2, 2018
Enrollment StartJul 26, 2018
Primary CompletionNov 29, 2020
Study CompletionNov 30, 2020
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 7.9 years ago
Interventions
BMS-986165drug
Specified dose on specified days
Placeboother
Specified dose on specified days
Apremilastdrug
Specified dose on specified days